Talk:Duvelisib

Patents

I haven't seen a table of patent info in other drug articles, so I'm wondering if it adds relevant info to the article here. It's an article about an experimental drug, so I can see the argument for including it because the topic is different than that of marketed drugs, but I'd like other opinions. Natureium (talk) 15:19, 19 January 2017 (UTC)

Very happy to see that gone. It is taken from pubchem which is not necessarily reliable for this subject of patents, and who ever added it to this article made some selection of patents listed in pubchem that is basically OR. Jytdog (talk) 17:35, 19 January 2017 (UTC)

I chopped out the table and left the one sentence explanation. Natureium (talk)

The long and twisty path to Verastem

Robert Forrester, CEO of Verastem, answered some questions about the way Duvelisib ended up at Verastem in the Nov 14, 2017 in the Q&A after his presentation at the Jefferies healthcare conference, and there is more to it than is explained in the wikipedia article. Some of it is hard to make out on the webcast, but it sounds extremely interesting. (Anyone can see the webcast, but this sort of presentation tends to disappear from the webcast after some small number of months.) 108.45.80.41 (talk) 08:47, 18 November 2017 (UTC)

This drug was considered as 'failed' by infinity, as NHL results in the duo study were not as planned. (There is a on almost emotional PR from Infinity on this). The CLL trial was ongoing, and the compound sold to Verastem, for little money. This year, the CLL trial had been found to be successful. Wowbagger2 (talk) 14:46, 27 December 2017 (UTC)

Request to add the sentence per FDA approval

Duvelisib, sold under the trade name Copiktra™, is a medication approved to treat a number of different forms of blood cancers. Citation: FDA https://www.fda.gov/Drugs/InformationOnDrugs/ApprovedDrugs/ucm621503.htm — Preceding unsigned comment added by 136.24.42.57 (talk) 20:55, 18 October 2018 (UTC) I agree that approval should be added at some point, but together with a comprehensive overview of efficacy and safety! Wowbagger2 (talk) —Preceding undated comment added 06:53, 19 October 2018 (UTC)

Medical Uses It is indicated for adult patients with chronic lymphocytic leukemia (CLL), small lymphocytic lymphoma (SLL), and follicular lymphoma (FL) who have received at least two prior therapies.

Adverse Effects The U.S. label for duvelisib has a boxed warning describing side effects that can be serious and fatal including infections, diarrhea or inflammation of the intestines, skin reactions, and inflammation of the lungs. Other serious side effects include abnormal liver blood tests and low white blood cell counts (neutropenia).

Reference: FDA <ref>https://www.fda.gov/Drugs/InformationOnDrugs/ucm623454.htm<ref> 136.24.42.57 (talk) 15:56, 23 October 2018 (UTC) comment added 08:53, 23 October 2018 (UTC)

As it has a boxed warning, the current already performed edits I highly recommend to delete - someone neutral person needs to take care of this article! Without this relevant label information, I think the article should not include commercial information. And yes - I have a COI (see my personal page). This is why I do not edit myself! Wowbagger2 (talk) 07:10, 24 October 2018 (UTC)